DK1426355T3 - Krystaller af hydroxynorephedrinderivater - Google Patents

Krystaller af hydroxynorephedrinderivater

Info

Publication number
DK1426355T3
DK1426355T3 DK02765352T DK02765352T DK1426355T3 DK 1426355 T3 DK1426355 T3 DK 1426355T3 DK 02765352 T DK02765352 T DK 02765352T DK 02765352 T DK02765352 T DK 02765352T DK 1426355 T3 DK1426355 T3 DK 1426355T3
Authority
DK
Denmark
Prior art keywords
crystals
hydroxynorephedrine
derivatives
hydroxynorephedrine derivatives
methylethylüaminoüethylü
Prior art date
Application number
DK02765352T
Other languages
Danish (da)
English (en)
Inventor
Hidetoshi Isawa
Yukihiko Hotei
Kiyoshi Kasai
Junichi Sonehara
Satoshi Akahane
Hiromu Harada
Original Assignee
Kissei Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kissei Pharmaceutical filed Critical Kissei Pharmaceutical
Application granted granted Critical
Publication of DK1426355T3 publication Critical patent/DK1426355T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/60Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
DK02765352T 2001-09-13 2002-08-27 Krystaller af hydroxynorephedrinderivater DK1426355T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001277345 2001-09-13
PCT/JP2002/008596 WO2003024916A1 (fr) 2001-09-13 2002-08-27 Cristaux d'un derive d'hydroxynorephedrine

Publications (1)

Publication Number Publication Date
DK1426355T3 true DK1426355T3 (da) 2009-02-23

Family

ID=19101883

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02765352T DK1426355T3 (da) 2001-09-13 2002-08-27 Krystaller af hydroxynorephedrinderivater

Country Status (29)

Country Link
US (1) US7208520B2 (ja)
EP (1) EP1426355B1 (ja)
JP (1) JP4157036B2 (ja)
KR (2) KR100874952B1 (ja)
CN (1) CN1275936C (ja)
AT (1) ATE411276T1 (ja)
AU (1) AU2002330453B2 (ja)
BR (1) BR0212494A (ja)
CA (1) CA2458544C (ja)
CO (1) CO5560555A2 (ja)
CY (1) CY1109409T1 (ja)
DE (1) DE60229404D1 (ja)
DK (1) DK1426355T3 (ja)
EA (1) EA006022B1 (ja)
EC (1) ECSP045017A (ja)
ES (1) ES2314092T3 (ja)
HK (1) HK1070051A1 (ja)
HR (1) HRP20040250A2 (ja)
HU (1) HUP0401694A3 (ja)
IL (2) IL160681A0 (ja)
MX (1) MXPA04002449A (ja)
NO (1) NO328252B1 (ja)
NZ (1) NZ531602A (ja)
PL (1) PL206246B1 (ja)
PT (1) PT1426355E (ja)
SI (1) SI1426355T1 (ja)
UA (1) UA77000C2 (ja)
WO (1) WO2003024916A1 (ja)
ZA (1) ZA200401757B (ja)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0210397D0 (en) 2002-05-07 2002-06-12 Ferring Bv Pharmaceutical formulations
ES2309513T3 (es) * 2003-05-05 2008-12-16 Kissei Pharmaceutical Co., Ltd. Uso de derivados de acido fenoxiacetico para tratar vejiga hiperactiva.
DE10351271A1 (de) * 2003-10-31 2005-06-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Zusammensetzung zur Behandlung der Stressinkontinenz und/oder Mischinkontinenz
AU2004285289A1 (en) * 2003-11-03 2005-05-12 Boehringer Ingelheim International Gmbh Pharmaceutical composition, containing a beta-3-adrenoceptor agonist and an alpha antagonist and/or a 5-alpha-reductase inhibitor
DE10352132A1 (de) * 2003-11-04 2005-06-09 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Zusammensetzung aus einem Beta-3-Adrenozeptor-Agonisten und einem Alpha Agonisten
WO2005092321A1 (ja) * 2004-03-24 2005-10-06 Kissei Pharmaceutical Co., Ltd. 頻尿または尿失禁の予防または治療用医薬組成物
JP4808613B2 (ja) * 2004-03-24 2011-11-02 キッセイ薬品工業株式会社 頻尿または尿失禁の予防または治療用医薬
DK1612203T3 (da) * 2004-06-28 2007-12-03 Gruenenthal Gmbh Krystallinske former af (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenolhydrochlorid
DE102004050952A1 (de) * 2004-10-18 2006-04-20 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Zusammensetzung zur Behandlung von Beschwerden, die mit krankhaften Veränderungen oder Irritationen der Prostata verbunden sind
CA2580170A1 (en) * 2004-10-18 2006-04-27 Boehringer Ingelheim International Gmbh Use of a beta-3 agonist for treating complaints of the prostate and the lower urogenital tract
US20090247781A1 (en) 2004-10-26 2009-10-01 Kissei Pharmaceutical Co., Ltd. Synthesis of phenoxyacetic acid derivatives
TWI356699B (en) * 2004-11-10 2012-01-21 Kissei Pharmaceutical Agent for treating interstitial cystitis and agent
EP1878719A4 (en) * 2005-04-26 2010-10-06 Kissei Pharmaceutical HYDROXYNOREPHEDRINE DERIVATIVE HYDROCHLORIDE POLYMORPH CRYSTAL
US8003694B2 (en) 2005-04-26 2011-08-23 Kissei Pharmaceutical Co., Ltd. Crystal of hydroxynorephedrin derivative hydrochloride ¼ hydrate
EP1769792A1 (de) 2005-09-30 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co.KG Verwendung eines beta-3-Adrenozeptor-Agonisten zur Behandlung von Nieren- und Blasenbeschwerden
RU2472539C2 (ru) 2007-08-06 2013-01-20 Аллерган, Инк. Способы и устройства для доставки препарата десмопрессина
US11963995B2 (en) 2008-05-21 2024-04-23 Ferring B.V. Methods comprising desmopressin
US20100286045A1 (en) 2008-05-21 2010-11-11 Bjarke Mirner Klein Methods comprising desmopressin
HUE030409T2 (en) 2008-05-21 2017-05-29 Ferring Bv Orodispersible desmopressin preparation to increase the length of the initial period of sleep disturbed by nocturia

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY126489A (en) * 1998-07-08 2006-10-31 Kissei Pharmaceutical Phenoxyacetic acid derivatives and medicinal compositions containing the same
JP4005731B2 (ja) * 1999-01-21 2007-11-14 キッセイ薬品工業株式会社 アミノエチルフェノキシ酢酸誘導体の結晶多形
JP4005730B2 (ja) * 1999-01-21 2007-11-14 キッセイ薬品工業株式会社 アミノエチルフェノキシ酢酸誘導体二水和物の結晶多形
JP4005729B2 (ja) * 1999-01-21 2007-11-14 キッセイ薬品工業株式会社 アミノエチルフェノキシ酢酸誘導体二水和物の結晶多形

Also Published As

Publication number Publication date
EP1426355A1 (en) 2004-06-09
CY1109409T1 (el) 2014-07-02
ES2314092T3 (es) 2009-03-16
WO2003024916A1 (fr) 2003-03-27
IL160681A0 (en) 2004-08-31
US20040242686A1 (en) 2004-12-02
EA006022B1 (ru) 2005-08-25
AU2002330453B2 (en) 2008-04-17
CN1275936C (zh) 2006-09-20
ATE411276T1 (de) 2008-10-15
BR0212494A (pt) 2004-08-24
CA2458544A1 (en) 2003-03-27
PT1426355E (pt) 2008-11-03
PL367874A1 (en) 2005-03-07
JPWO2003024916A1 (ja) 2004-12-24
HUP0401694A3 (en) 2008-03-28
EP1426355B1 (en) 2008-10-15
EP1426355A4 (en) 2006-03-29
KR100874952B1 (ko) 2008-12-19
CN1553890A (zh) 2004-12-08
MXPA04002449A (es) 2004-07-23
ZA200401757B (en) 2005-03-03
KR20080098691A (ko) 2008-11-11
NO328252B1 (no) 2010-01-18
JP4157036B2 (ja) 2008-09-24
CO5560555A2 (es) 2005-09-30
HRP20040250A2 (en) 2005-02-28
IL160681A (en) 2010-06-16
KR20040044881A (ko) 2004-05-31
PL206246B1 (pl) 2010-07-30
HUP0401694A2 (hu) 2004-11-29
EA200400311A1 (ru) 2004-08-26
ECSP045017A (es) 2004-09-27
CA2458544C (en) 2010-08-17
NZ531602A (en) 2006-01-27
UA77000C2 (en) 2006-10-16
HK1070051A1 (en) 2005-06-10
DE60229404D1 (de) 2008-11-27
SI1426355T1 (sl) 2009-02-28
US7208520B2 (en) 2007-04-24
NO20041060L (no) 2004-06-11

Similar Documents

Publication Publication Date Title
HK1070051A1 (en) Crystals of hydroxynoorephedrine derivative
IS2750B (is) Leiðarafesting
MXPA04002167A (es) Inhibidores de la 17 beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades androgeno-dependientes.
NO20020968L (no) Glukopyranosyloksypyrazolderivater, medisinske sammensetninger inneholdende det samme og intermediater forfremstillingen derav
NO20051209L (no) Pyrazolderivater, medisinske sammensetninger inneholdende slike, medisinsk anvendelse derav samt intermediater for samme
CY1109880T1 (el) ΑΝΤΑΓΩΝΙΣΤΗΣ CaSR
BR0210383A (pt) compostos para o tratamento de distúrbios metabólicos
PT1259489E (pt) Compostos azapoliciclicos condensados con arilo.
DK1767535T3 (da) Syntese af epothiloner, mellemprodukter deraf, analoge og deres anvendelse
SE0201544D0 (sv) Novel compounds and thier use
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
NO304113B1 (no) Krystallinsk tiagabinhydrokloridmonohydrat, farmas°ytisk preparat som omfatter det, og anvendelse derav for fremstilling av et medikament
CY1111857T1 (el) Κρυσταλλικη βαση trans-1-((1r,3s)-6-xλωpo-3-φαινυλινδαν-1-υλο)-3,3-διμεθυλοπιπεραζινης
WO2004041802A8 (en) 4(phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain or gastrointestinal disorders
NO20050903L (no) Nye piperazinyl-pyrazinonderivater for behandling av 5HT-2A reseptorrelaterte forstyrrelser
IS6087A (is) N-(2-fenýl-4-amínó-bútýl)-1-naftamíð sem virka á móti taugakínín-1 viðtaka
BRPI0513549A (pt) composições farmacêuticas para o tratamento de leishmaniose
BR0114395A (pt) Composição farmacêutica para administração por suprimento via oral
SE0104333D0 (sv) Therapeutic agents
EA200501433A1 (ru) Система подкожной доставки, способ ее получения и ее применение для лечения холинергических дефицитных расстройств
ATE295845T1 (de) Prucaloprid-n-oxid
DK1496904T3 (da) Anvendelse af lægemidler indeholdende N,N'-disubstituerede piperazinforbindelser
DE60117472D1 (de) Pharmazeutische zusammensetzung zur behandlung von fettleibigkeit
ITTO20040343A1 (it) Uso di neboglamine (cr2249) come neuropsicotico e neuroprotettivo